Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In Focus

Vertex Pharmaceuticals (VRTX) stepped into the spotlight after new interim ALYFTREK data at the North American Cystic Fibrosis Conference suggested some young children regained pancreatic function and were able to stop enzyme replacement therapy. For context, Vertex Pharmaceuticals has given investors a mixed near term ride, with the 1 day share price return down 1.77% and the 30 day share price return down 2.63%, yet the 90 day share price return up 2.90% and the year to date share price...